3 recruiting, 1 not yet recruiting. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow CTX112: new trials by email Literature Review of CTX112 trials Research Report on CTX112
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease CTX112 - SLE (Systemic Lupus), Lupus Erythematosus, Systemic | Phase 1 | Recruiting | CRISPR Therapeutics | 80 | 2025-03-10 | 2026-10-26 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 120 | 2023-03-10 | 2025-11-14 |
Autoimmune Diseases of the Nervous System (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Sclerosis, Chronic Progressive (1) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1) · Myositis (1) · Neuromyelitis Optica (1) · Purpura, Thrombocytopenic, Idiopathic (1)
CRISPR Therapeutics (2) · CRISPR Therapeutics AG (2)
United States (3) · Germany (2) · Spain (2) · Australia (1)